News
Press Releases and Media
Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session
Fully Automated 3D Segmentation and Quantitation of the Amyloidophilic Radiotracer Iodine Evuzamitide (124i-P5+14, AT-01) in the Heart of Patients with Systemic Amyloidosis and Healthy Subjects
Detection of Cardiac Amyloidosis in Patients with Systemic AL and ATTR Amyloidosis Using Iodine Evuzamitide PET/CT Imaging and the Correlation with Serum NT-proBNP
Attralus Appoints James Testa as Vice President of Finance
Attralus is Developing a New Treatment for Systemic Amyloidosis
Patient Worthy
Podcast Edition: Jonathan Wall, PhD
OncologyTube
Attralus Presents Positive New Data at 2021 American Society of Hematology Annual Meeting
Detection of Systemic AL Amyloidosis by 124I-p5+14 PET/CT imaging – Providing the Complete Picture for Diagnosis
Pre-Clinical Characterization of a Novel Fusion Protein (AT-03), with Pan-Amyloid Binding and Removal
Attralus to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
Attralus to Present New Data at 2021 American Society of Hematology Annual Meeting
Amyloidosis therapy PAR excellence? Attralus draws $116M series B
BioWorld
Attralus Closes $116 Million Series B Financing
Meet the 24 biotech startups that top VCs say are poised to take off in the next 12 months
Business Insider
Meet the 24 biotech startups that top VCs say are poised to take off in the next 12 months
Business Insider
Note: Source article is behind a pay wall.
BioSpace Movers & Shakers, July 30, 2021
BioSpace
Attralus Appoints Jake Bauer to Board of Directors
Synthesis of 99m Tc-labeled Peptide p5+14 for Detection of Cardiac Amyloidosis – Preclinical Studies in a Mouse Model
Poster Number 3007
Attralus Announces Presentation of Clinical Data on AT-01, a Novel Diagnostic for Systemic Amyloidosis, at the 2021 Society of Nuclear Molecular Imaging Meeting
Presentation: Multi-amyloid Reactivity of the Peptide Imaging Agent 124I-p5+14 (AT-01) in Patients with Amyloidosis
Clinical Utility of PET/CT Imaging with Peptide Imaging Agent 124I-p5+14 (AT-01) in Patients with Systemic Amyloidosis
Quantification of Peptide 124I-p5+14 (AT-01) Uptake in Patients with Systemic Amyloidosis
AT-01 Can Detect Amyloid Deposits in Heart of Asymptomatic Patients
FAP News Today
Detection and Differentiation of Cardiac Amyloidosis Using [124]I-P5+14 PET/CT Imaging and the Correlation with Clinical Biomarkers
Attralus Announces Presentation of Clinical Data on AT-01, a Novel, Potential First-in-Class Diagnostic for Systemic Amyloidosis at the 2021 American College of Cardiology Annual Meeting
Attralus Appoints Mark Timney as CEO and Expands Leadership Team with New Executives
Imaging Agent Can Help Differentiate Between Amyloidosis Types
FAP News Today
Attralus Presents Clinical Data from Novel, Potential First-in-Class Diagnostic AT-01 for Systemic Amyloidosis at Virtual ASH 2020
Attralus to Present Clinical Data at Upcoming Virtual ASH 2020
Reversing disease pathology in amyloidosis: Attralus launches with $25m Series A
Pharmaceutical Technology
Attralus Eyes Further Work on Therapeutic Candidates with New Funding
www.biospace.com
The Crunchbase News Briefing: Mon., Sept. 14
news.crunchbase.com
Attralus Raises $25M in Series A Financing
finsmes.com
Attralus Secures $25M Series A to Diagnose and Treat Amyloidosis
timmermanreport.com
Note: Source article is behind a pay wall.
Attralus debuts with $25M series A to tackle systemic amyloidosis
biocentury.com
Note: Source article is behind a pay wall.
Attralus Raises $25 Million to Transform Treatment for Patients with Systemic Amyloidosis
globalgenes.org
Attralus Presents Preclinical and Clinical Data at 17th International Symposium on Amyloidosis
Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis
prnewswire.com
Aurora Bio, Inc Announces Clinical Data on Lead Program
businesswire.com